Chronic inflammation → interstitial fibrosis, tubular atrophy, and secondary glomerulosclerosis.
Clinical & Public-Health Implications
Analgesic nephropathy is preventable; highlights the need for:
• Regulatory limits on compound analgesic availability.
• Patient education regarding dose and duration.
• Routine renal monitoring in chronic pain patients.
Ethical dimension: balancing OTC accessibility with population safety.
Differential Diagnostic Points (Contextual)
Must distinguish from:
• Chronic ischemic nephropathy due to renovascular disease.
• Diabetic papillary necrosis.
• Reflux nephropathy.
Key clues favoring analgesic nephropathy: bilaterally small bumpy kidneys + papillary necrosis + history of analgesic overuse.
Take-Home Messages
Prolonged high-dose analgesic use can precipitate irreversible renal injury.
Pathognomonic gross features: small, granular kidneys with papillary necrosis and cortical cysts.
Mechanisms integrate vascular dysregulation, direct cytotoxicity, and obstructive sequelae.
Clinical vigilance and policy interventions are critical to curb this entirely avoidable pathology.